Active, not recruitingPhase 3NCT04490915
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Studying Congenital adrenal hyperplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neurocrine Biosciences
- Principal Investigator
- Clinical Development LeadNeurocrine Biosciences
- Intervention
- Crinecerfont(drug)
- Enrollment
- 182 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (30)
- Neurocrine Clinical Site, Los Angeles, California, United States
- Neurocrine Clinical Site, San Diego, California, United States
- Neurocrine Clinical Site, San Francisco, California, United States
- Neurocrine Clinical Site, Aurora, Colorado, United States
- Neurocrine Clinical Site, Atlanta, Georgia, United States
- Neurocrine Clinical Site, Indianapolis, Indiana, United States
- Neurocrine Clinical Site, Bethesda, Maryland, United States
- Neurocrine Clinical Site, Boston, Massachusetts, United States
- Neurocrine Clinical Site, Ann Arbor, Michigan, United States
- Neurocrine Clinical Site, Minneapolis, Minnesota, United States
- Neurocrine Clinical Site, Rochester, Minnesota, United States
- Neurocrine Clinical Site, St Louis, Missouri, United States
- Neurocrine Clinical Site, Great Neck, New York, United States
- Neurocrine Clinical Site, New York, New York, United States
- Neurocrine Clinical Site, Winston-Salem, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04490915 on ClinicalTrials.govOther trials for Congenital adrenal hyperplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07159841A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)Crinetics Pharmaceuticals Inc.
- RECRUITINGPHASE3NCT07144163A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaCrinetics Pharmaceuticals Inc.
- RECRUITINGPHASE2NCT07187375Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years OldNeurocrine Biosciences
- RECRUITINGNANCT07473804Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)IRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06712823An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894Crinetics Pharmaceuticals Inc.
- RECRUITINGNANCT07099456Fertility And Sexual Function In CAH: CALLIOPEUniversity of Roma La Sapienza
- RECRUITINGPHASE1, PHASE2NCT05669950A Trial of Lu AG13909 in Participants With Congenital Adrenal HyperplasiaH. Lundbeck A/S
- RECRUITINGNCT06754423Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase DeficiencyIRCCS Azienda Ospedaliero-Universitaria di Bologna